110957 ⎘
ssRNA viruses negative-sense; Details; Paramyxoviridae; Morbillivirus, e.g. Measles virus, canine distemper New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
HUMAN CTLA-4 PEPTIDE VACCINES AND USES THEREOF
#2FUSOSOME COMPOSITIONS AND USES THEREOF
#3RNA VIRUS-DERIVED CHIMERIC ENVELOPE PROTEIN AND RNA VIRUS VECTOR HAVING SAME
#4ANTI-CD90 ANTIBODIES, BINDING FRAGMENTS, AND USES THEREOF
#5METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#6LIQUID-LIQUID PHASE SEPARATION (LLPS)-BASED COMPARTMENTS COMPRISING A SHORT PEPTIDE AND AN ANIONIC POLYMER
#7ENGINEERED VIRAL PARTICLES AND USES OF THE SAME
#8COMPOSITIONS AND METHODS FOR MULTIVALENT SURFACE DISPLAY ON ENVELOPED PARTICLES
#9RETARGETED RETROVIRAL VECTORS RESISTANT TO VACCINE-INDUCED NEUTRALIZATION AND COMPOSITIONS OR METHODS OF USE THEREOF
#10RETARGETED RETROVIRAL VECTORS AND COMPOSITIONS OR METHODS OF USE THEREOF
#11AMINO ACIDS, NUCLEOTIDES AND VECTORS EXPRESSING THE SAME AND USES THEREOF IN PREVENTING SARBECOVIRUS INFECTION
#12ANTIBODY-BASED ANTIVIRUS COMPOSITIONS AND METHODS OF USE
#13ENGINEERING HEMAGGLUTININ AND FUSION POLYPEPTIDES OF CANINE DISTEMPER VIRUS
#14METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF
#15MEASLES-HIV OR MEASLES-HTLV VACCINE
#16CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES
#17REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES
#18METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS
#19Methods and compositions for transducing lymphocytes and regulating the activity thereof
#20TARGETING PD-L1 ON TUMOR CELLS
#21Paramyxovirus vaccine strain for novel coronavirus pneumonia and construction method thereof
#22TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA
#23Modified viruses
#24CD62L specific lentiviral vector particle for targeted transduction of T cell subsets
#25RECOMBINANT RSV LIVE VACCINE STRAIN AND PRODUCTION METHOD THEREFOR
#26FUSOSOME COMPOSITIONS AND USES THEREOF
#27Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#28Optically controlled virus protein, gene thereof, and virus vector containing said gene
#29Replication-competent vesicular stomatitis viruses
#30Modified viruses
#31Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#32Targeting PD-L1 on tumor cells
#33Nipah virus envelope glycoprotein pseudotyped lentivirus
#34Tunable vaccine platform against pathogens of the paramyxovirus family
#35Replication-competent vesicular stomatitis viruses
#36Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening
#37Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#38Treatment of cancer using recall antigens delivered by attenuated bacteria
#39Methods and compositions for transducing lymphocytes and regulating the activity thereof
#40Gene-modified measles virus for tumor treatment use
#41VIRUS VECTOR, CELL, AND CONSTRUCT
#42Methods and compositions for transducing lymphocytes and regulated expansion thereof
#43Replication-competent vesicular stomatitis viruses
#44Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
#45Recombinant CDV compositions and uses thereof
#46Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#47NOVEL PSEUDOTYPED LENTIVIRAL PARTICLES AND THEIR USE IN THE IN VITRO TARGETED TRANSDUCTION OF UNDIFFERENTIATED PLURIPOTENT HUMAN EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS
#48Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#49Compositions and methods for measles virus inhibition
#50Replication-competent vesicular stomatitis viruses
#51Viruses lacking epithelial cell receptor entry
#52Cells and methodology to generate non-segmented negative-strand RNA viruses
#53Compositions and methods for coronavirus inhibition
#54Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#55Feline morbillivirus and uses thereof
#56Vectors and methods for transducing B cells
#57Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions
#58Treatment of influenza virus infection
#59Chimeric VEGF Peptides
#60METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS
#61CDNA corresponding to the antigenome of nonsegmented negative strand RNA viruses, and process for the production of such viruses encoding additional antigenically active proteins
#62Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes
#63FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS
#64Recombinant CDV compositions and uses thereof
#65MEASLES VIRUS FOR THE ELIMINATION OF UNWANTED CELL POPULATIONS
#66Viruses lacking epithelial cell receptor entry
#67ANTI-MEASLES CANCER IMMUNOTHERAPY
#68METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
#69Use of Measles Virus Nucleoprotein for Treating Atherosclerosis
#70COMPOSITION AND METHOD FOR TREATING VIRAL INFECTION
#71Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening
#72Cells and methodology to generate non-segmented negative-strand RNA viruses
#73Naturally processed measles virus peptides from class II HLA molecules
#74Preparation of soluble N-protein/truncated P-protein complexes of the paramyxoviridae family
#75Influenza virus inhibiting peptides
#76METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS
#77USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL
#78Compositions and Methods for Elimination of Unwanted Cells
#79Compositions and Methods for Elimination of Unwanted Cells
#80Compositions and Methods for Elimination of Unwanted Cells
#81Compositions and methods for elimination of unwanted cells
#82cDNA corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses
#83Infectious recombinant paramyxovirus from antigenomic cDNA
#84T helper cell epitopes
#85Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
#86Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#87Immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes
#88Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#89Influenza virus inhibiting peptides
#90T helper cell epitopes
#91Method for the recovery of non-segmented, nagative-stranded RNA viruses from cDNA
#92Naturally processed measles virus peptides eluted from class II HLA molecules
#93Compositions and methods for elimination of unwanted cells
#94Naturally processed measles virus peptides eluted from class II HLA molecules
#95Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2.
#96Recombinant measles viruses expressing epitopes of antigens of RNA viruses - use for the preparation of vaccine compositions
#97Ablated SLAM-Dependent Entry
#98Recombinant therapeutic fusion proteins
#99Chimeric VEGF peptides
#100Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions
#101T helper cell epitopes
#102Rescue of canine distemper virus from cdna
#103T helper cell epitopes